Schrödinger adds another Big Pharma partner; Grey Wolf bags $3.3M to 'illuminate' tumors
→ Schrödinger has added yet another large pharma company to its list of partners. The New York-based biotech signed a €10 million ($11 million) deal to improve Bayer‘s drug discovery efforts. As with their existing collaborations with AstraZeneca and Sanofi, Schrödinger will use their machine learning-based molecular design technology to screen billions of compounds to identify and optimize drug targets. The news comes as Schrödinger aims to develop its own clinical programs with three cancer targets, hiring translational veterans from Merck and Eisai to do so.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.